CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (109,818,000)	$ (114,206,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	30,872,000	26,475,000
Amortization of inventory step-up	365,000	5,315,000
Allowance for credit losses and inventory reserves	3,343,000	478,000
Share-based compensation, including restructuring costs	55,360,000	36,571,000
Amortization of discount and cost of issuance of debt	788,000	747,000
Asset impairment in relation to restructuring	998,000	0
Loss from change in fair value of warrants	0	6,626,000
Gain from change in fair value of contingent considerations and acquisition-related holdbacks	(28,167,000)	(4,208,000)
Loss from change in fair value of currency forward contract	701,000	298,000
Deferred tax liabilities	0	(8,731,000)
Amortization of right-of-use assets	2,504,000	1,917,000
Changes in operating assets and liabilities:
Accounts receivable	8,673,000	(13,048,000)
Inventory	(17,238,000)	(12,489,000)
Accounts payable	7,910,000	(654,000)
Accrued expenses and other current liabilities	(5,064,000)	(2,354,000)
Accrued payroll liabilities	1,746,000	110,000
Prepaid and other current assets	(1,332,000)	(13,896,000)
Operating lease liabilities	(2,383,000)	(1,670,000)
Other long-term liabilities	(1,135,000)	4,742,000
Net cash used in operating activities	(51,877,000)	(87,977,000)
Cash flows from investing activities:
Purchases of property and equipment	(12,504,000)	(8,580,000)
Payments for acquired software license	(1,022,000)	0
Business combinations, net of cash acquired	(3,200,000)	(94,989,000)
Net cash used in investing activities	(16,726,000)	(103,569,000)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	13,234,000	51,998,000
Proceeds from issuance of short-term debt obligations	17,194,000	1,717,000
Issuance costs on line of credit	(50,000)	0
Payments on debt obligations	(2,048,000)	(12,514,000)
Payments on financed software	(4,429,000)	(7,037,000)
Deferred payments on business combination	(500,000)	0
Proceeds from exercise of stock options	53,000	31,000
Net cash provided by financing activities	23,454,000	34,195,000
Effect of exchange rate changes on cash and cash equivalents	668,000	(3,880,000)
Net decrease in cash and cash equivalents	(44,481,000)	(161,231,000)
Cash, cash equivalents and restricted cash at beginning of period	151,678,000	321,879,000
Cash, cash equivalents and restricted cash at end of period	107,197,000	160,648,000
Reconciliation of amounts on condensed consolidated balance sheet:
Cash and cash equivalents	96,897,000	160,648,000
Restricted cash	10,300,000	0
Total cash, cash equivalents and restricted cash	107,197,000	160,648,000
Supplemental disclosure of cash flow information:
Cash paid for interest	3,787,000	3,807,000
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	134,000	243,000
Fair value of common stock issued for business combination	0	128,182,000
Fair value of common stock issuable for business combination	0	23,479,000
Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks	49,760,000	0
Contingent consideration for business combination	4,599,000	86,297,000
Accrual for purchase consideration for business combination	800,000	4,264,000
Fair value of common stock issued for investment in Expedera	$ 3,428,000	$ 0